Celyad Raises $100.1 Million Gross Proceeds With NASDAQ IPO

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Celyad Raises $100.1 Million Gross Proceeds With NASDAQ IPO

MONT-SAINT-GUIBERT, Belgium, June 18, 2015 (GLOBE NEWSWIRE) -- Celyad SA (formerly known as Cardio3 BioSciences) (Euronext Brussel:CYAD) (Paris: CYAD ), today announced the pricing of its global offering totaling $100.1 million gross proceeds of 1,460,000 new ordinary shares, consisting of 1,168,000 American Depositary Shares ("ADSs") at $68.56 per ADS, and 292,000 ordinary shares at a price of EUR 60.25 per share, both before underwriting discounts. These shares were placed in a concurrent public offering in the United States and private placement in Europe (together the "global offering"). The price per ADS was based on EUR 60.25 per ordinary share at an exchange rate of $ 1.1380 per Euro.

In addition, Celyad has granted the underwriters an option to purchase up to an additional 175,200 new ordinary shares in the form of ADSs and an option to purchase up to an additional 43,800 new ordinary shares, representing 15% of the ordinary shares and ADSs placed in the global offering. This option can be exercised during the 30 day period commencing 18 June 2015.

The closings of the ADS offering and the concurrent private placement are conditioned on each other and are expected to occur on 24 June 2015, subject to customary closing conditions.

Each of the ADSs offered represents the right to receive one ordinary share.

Celyad's ordinary shares are currently listed on Euronext Paris and Euronext Brussels, under the symbol "CYAD". The ADSs are expected to begin trading on the NASDAQ Global Select Market on 19 June 2015 under the symbol "CYAD".

UBS Investment Bank and Piper Jaffray & Co. are acting as joint book-running managers, and Petercam SA, Bryan, Garnier & Co., LifeSci Capital LLC and Lake Street Capital Markets LLC are acting as co-managers for the proposed global offering.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on 18 June 2015.

The securities to be issued in the global offering are being offered only by means of a prospectus. A copy of the final prospectus, when available, can be obtained from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, or by telephone at (888) 827-7275; Piper Jaffray & Co. Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@pjc.com .

This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For more information, please contact:

For Europe : Consilium Strategic Communications
Amber Bielecka , Chris Welsh , and Laura Thornton - T: +44 (0)20 3709 5700 - celyad@consilium-comms.com
 
For the U.S. : The Ruth Group
Lee Roth (Investors), and Kirsten Thomas (Media) - T: +1 646 536 7012 / 7014 -   celyad@theruthgroup.com
 
For France : NewCap
Pierre Laurent and Nicolas Mérigeau -   T: + 33(0)1 44 71 94 94 - celyad@newcap.fr
 
Celyad
Christian Homsy , CEO and Patrick Jeanmart , CFO : T: +32 (0)10 39 41 00   info@celyad.com
 

To subscribe to Celyad's newsletter, visit www.celyad.com   Follow us on Twitter @CelyadSA

About Celyad

Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. Celyad is developing its lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure, and has completed enrolment of a Phase III trial in Europe and Israel. In addition, the Company is developing a novel portfolio of CAR T-cell therapies that utilize human Natural Killer cell receptors for the treatment of numerous blood and solid cancers. Its lead oncology product candidate, NKG2D CAR T-cell, entered a Phase I clinical trial in April 2015.

Celyad's shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CYAD.

To learn more about Celyad, please visit www.celyad.com .

Forward looking statements

In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure® and Phase I clinical trial for NKG2D CAR T-cell additional clinical results validating the use of adult autologous stem cells to treat heart failure and CAR T-cell autologous therapy to treat cancer; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties, competition from others developing products for similar uses, our ability to manage operating expenses, and our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and business initiatives. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

C3BS-CQR-1, C-Cure, NKG2D CAR T-cell, C-Cath ez , OnCyte, Celyad, Cardio3 BioSciences and the Cardio3 BioSciences, Celyad, C-Cath ez , CHART-1, CHART-2 and OnCyte logos are signs internationally protected under applicable Intellectual Property Laws. Mayo Clinic holds equity in Celyad as a result of intellectual property licensed to the Company.

Important information

This press release is not an offer to sell nor a solicitation to buy the new shares nor a prospectus for the purposes of Directive 2003/71/EC (such Directive, together with any applicable implementing measures in the relevant member state of the European Economic Area and as amended, including by Directive 2010/73/EU, to the extent implemented in the relevant member state, the "Prospectus Directive"). There will be no offer to the public of the new shares in any member state of the European Economic Area and no prospectus or other offering document has been or will be prepared in connection with the sale of the new shares by the Company in the European Economic Area. In the European Economic Area the new shares will only be offered and sold to "qualified investors" as defined in the Prospectus Directive or in other circumstances falling within Article 3(2) of the Prospectus Directive.

This press release does not constitute an offer of the new shares to the public in the United Kingdom, nor is it intended to be an inducement to engage in investment activity for the purpose of section 21 of the Financial Services and Markets Act 2000 (as amended) of the United Kingdom. Consequently, this press release is only directed at (i) persons who are outside the United Kingdom; (ii) investment professionals within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 as amended (the "Order"); (iii) persons falling within Article 49(2)(a)-(d) of the Order; or (iv) other persons to whom it may be lawfully be communicated, together being referred to as "relevant persons". The new shares are only available to, and any invitation, offer or agreement to purchase or otherwise acquire the new shares will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 25

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 19

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 19

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 16

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 80

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 88

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 30

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 5

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 37

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading

Top 5 Most Recently Viewed Articles

Homrich Berg Welcomes Tim Tallach as New Tax Director

Updated Category News Views 319

Homrich Berg Welcomes Tim Tallach as Director Atlanta-based Homrich Berg, a prominent fee-only wealth advisor recognized for its comprehensive services, proudly announces the addition of Tim Tallach, J.D., CPA, as its new Director of Advanced Tax Planning and Family Office Services. This important addition to the team aims to fortify the firm's capabilities in serving...

Continue Reading
G-III Apparel Group Schedules First Quarter Earnings Call

Updated Category News Views 168

G-III Apparel Group Prepares for Earnings Announcement G-III Apparel Group, Ltd. (NASDAQ: GIII) is a prominent entity in the global fashion industry, recognized for its innovative design, sourcing, and marketing capabilities. The company has recently made an announcement regarding its first quarter fiscal 2026 earnings. This significant event is scheduled to take place...

Continue Reading
Mediaplanet's Initiative to Empower Small Businesses Nationwide

Updated Category News Views 117

Mediaplanet's Campaign for Small Business Success Small businesses play a pivotal role in stimulating the economy by fostering innovation, generating employment, and enhancing community engagement. However, in the face of today's complex business challenges, many entrepreneurs require support to navigate these waters successfully. To address this need, Mediaplanet has...

Continue Reading
New Barclays Report Highlights AI's Impact on Data Centre Demand

Updated Category News Views 529

Revolutionizing Data Centres: Insights from Barclays Research In a groundbreaking report, Barclays Research reveals that the rising influence of artificial intelligence (AI) could propel data centre usage in the US to triple by 2030. This report, titled “AI revolution: Meeting massive AI infrastructure demands,” presents a comprehensive analysis of how AI's growth...

Continue Reading
Major Renovation Completed at Aloft Phoenix-Airport Hotel

Updated Category News Views 274

Aloft Phoenix-Airport Unveils Major Renovation In an exciting development for travelers, the Aloft Phoenix-Airport has completed a comprehensive renovation that significantly upgrades its facilities. This 143-room hotel, managed by HEI Hotels & Resorts and owned by The RADCO Companies, has refreshed everything from guest rooms to public spaces, ensuring a modern and...

Continue Reading